Insider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Buys 7,000 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Jean Jacques Bienaime purchased 7,000 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was bought at an average cost of $8.21 per share, with a total value of $57,470.00. Following the completion of the purchase, the director now owns 23,615 shares of the company's stock, valued at $193,879.15. This represents a 42.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Immunome Price Performance

IMNM stock traded down $0.29 during trading on Friday, hitting $6.99. 1,060,189 shares of the stock traded hands, compared to its average volume of 854,933. The stock has a market cap of $607.79 million, a price-to-earnings ratio of -0.86 and a beta of 1.93. Immunome, Inc. has a 1 year low of $6.90 and a 1 year high of $24.87. The firm's 50 day moving average is $9.50 and its two-hundred day moving average is $11.31.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. As a group, analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Stephens reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Guggenheim reduced their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Wedbush reissued an "outperform" rating and set a $33.00 price target on shares of Immunome in a research report on Thursday, March 20th. Finally, Lifesci Capital assumed coverage on shares of Immunome in a report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome currently has an average rating of "Buy" and a consensus target price of $25.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in shares of Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company's stock worth $6,469,000 after purchasing an additional 302,916 shares in the last quarter. Geode Capital Management LLC increased its position in Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock worth $17,657,000 after buying an additional 144,557 shares in the last quarter. Magnus Financial Group LLC raised its stake in shares of Immunome by 107.8% in the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company's stock worth $569,000 after buying an additional 27,777 shares during the period. Point72 Asset Management L.P. lifted its position in shares of Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company's stock valued at $6,881,000 after buying an additional 85,580 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Immunome by 125.9% during the 3rd quarter. Barclays PLC now owns 105,886 shares of the company's stock valued at $1,547,000 after acquiring an additional 59,016 shares during the period. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.